Virios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcript

We anticipate meeting with the FDA in the second half of this year to discuss opening a new investigational drug application, as Mike referenced, to more formally assessed treatment center of symptoms for patients with long-COVID and potentially a broader fatigue syndromes using our second development candidate, IMC-2, which as you’re probably well aware, but completeness is a fixed-dose combination of valacyclovir and celecoxib. As Mike also mentioned, we plan to execute the confirmatory study used IMC-2 as a treatment for long-COVID under double-blind placebo-controlled conditions. This study is fully funded. We plan to commence the study starting early fall. We will work closely with the FDA, as you would well imagine to determine our next steps in advancing both of these very promising programs and look forward to providing consistent updates over the course of the second half of this year.

We want to thank you all for your interest in Virios and for attending today’s earnings update. We’re pleased to tell you that our pipeline now has very two significant opportunities, and we are committed to advancing those opportunities as expeditiously as possible with the goal of getting both IMC-1 and IMC-2 into the market to help millions of patients who suffer from fibromyalgia and/or long-COVID sequelae. Thank you for attending today’s call.

Operator: Thank you. This does conclude today’s conference. You may disconnect your lines at this time, and have a wonderful day. Thank you for your participation.